Teneliximab (Chi220) is a chimeric monoclonal antibody and a tumor necrosis factor receptor superfamily member 5 (CD40) inhibitor that blocks CD40-CD40L interactions.Teneliximab exerts partial agonist activity through CD40 and peripheral B-cell depletion, and may be used to study organ transplant rejection and rheumatoid arthritis.

RMP1-14 is an IgG1-like immunoglobulin and anti-Mouse PD-1 antibody that blocks PD-1/PD-L1 signaling.

Anti-Mouse CD8a Antibody is a rat-derived IgG2a isotype inhibitor specific for mouse CD8a.

Anti-Mouse CD90.2 Antibody is a rat-derived IgG2b inhibitor targeting mouse CD90.2.

Anti-Mouse CD54 Antibody is a rat-derived IgG2b inhibitor targeting mouse CD54.

Anti-Mouse CTLA-4 Antibody is a mouse-derived IgG2b inhibitor targeting CTLA-4 in murine systems.

Anti-Mouse PD-L1 Antibody is a rat-derived IgG2b monoclonal antibody that inhibits mouse PD-L1.

The Anti-Mouse CD11b Antibody is a rat-derived IgG2b monoclonal antibody that targets the CD11b antigen on mouse cells.

Anti-Mouse IL-1b Antibody is an IgG inhibitor specific to mouse IL-1b, derived from an Armenian Hamster host.

Anti-Mouse H-2K Antibody is an IgG2b isotype inhibitor targeting the mouse H-2K antigen, sourced from a murine host.

Anti-Mouse CD90 Antibody is a Rat-derived IgG2b inhibitor targeting mouse CD90.

Anti-Mouse Ly-6G/Ly-6C Antibody is an IgG2b isotype antibody that targets both Ly-6G and Ly-6C antigens on mouse cells, functioning as an inhibitor.

Anti-Mouse TCR V gamma 2 Antibody is a host Armenian Hamster-derived IgG inhibitory antibody targeting mouse TCR V gamma 2.

Anti-Mouse CD11a Antibody is a rat-derived IgG2b inhibitor specific to the mouse CD11a molecule.

Anti-Mouse LAG-3 is a rat-derived IgG1 antibody inhibitor targeting mouse LAG-3.

Anti-Mouse IL-1R Antibody is an IgG2b subclass inhibitor targeting the mouse IL-1 receptor, sourced from Armenian hamsters.

Anti-Mouse CD209b Antibody is an IgG1 inhibitor targeting mouse CD209b, sourced from the Armenian Hamster.

Anti-Mouse CD8 beta Antibody is a rat-derived IgG1 inhibitor targeting the mouse CD8 beta protein.

Anti-Mouse IFN Gamma Antibody is a host Armenian Hamster-derived anti-mouse IFN gamma immunoglobulin G (IgG) inhibitor.

Anti-Mouse CD3 Antibody is a Rat-derived IgG2b isotype inhibitor targeting the mouse CD3 complex.

Anti-Mouse CD32/CD16 Antibody is a rat-derived IgG2b inhibitor targeting the mouse CD32/CD16 antigens.

The Anti-Mouse CD44 Antibody is a rat-derived IgG2b inhibitor targeting mouse CD44.

Anti-Mouse TCR gamma/delta Antibody is a host Armenian Hamster-derived IgG class inhibitor targeting the mouse TCR gamma/delta receptor.

Anti-Mouse TNF alpha Antibody is a rat-derived IgG inhibitor targeting mouse TNF alpha.

Anti-Mouse TNFR2 Antibody is an Armenian Hamster-derived IgG inhibitor specifically targeting mouse TNFR2.

Anti-Mouse NK1.1 Antibody (PK136) is an IgG2a class antibody of murine origin targeting NK1.1, which eliminates NK1.1 and NK1.1NKT cells and inhibits NK1.1 signaling in peripheral blood, spleen, and lung tissues, and can be used in the study of heart and lung failure.

Anti-Mouse CD28 Antibody is a Syrian Hamster-derived IgG inhibitor targeting mouse CD28.

Talizumab (TNX 901), a humanized IgG1 monoclonal antibody, targets IgE [1].

Rontalizumab, a humanized IgG1 monoclonal antibody, targets IFN-α and is utilized in research on systemic lupus erythematosus[1].

Ligelizumab (QGE 031), a high-affinity humanized monoclonal anti-IgE antibody, is utilized in the research of chronic spontaneous urticaria [1].

Bleselumab (ASKP 1240), a human anti-CD40 monoclonal antibody (mAb), exhibits high-affinity binding to CD40 (Kd: 0.24 nM) and hinders immune responses by impeding the CD40-CD40L interaction, thereby preventing organ transplant rejection [1].

Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody that targets the CD4 molecule and effectively inhibits T-cell receptor (TCR) signal transduction. It is used in the research of rheumatoid arthritis, psoriasis, melanoma, cutaneous, and peripheral T-cell lymphoma [1].

Varisacumab (R 84) is an antibody utilized in diverse biochemical analyses [1].

Naratuximab emtansine [1] is a humanized monoclonal antibody (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) that specifically targets CD37 (TSPAN26) and serves as the basis for creating an antibody-drug conjugate (ADC) compound.

Inclacumab, a humanized monoclonal IgG4 antibody (Anti-Human Selectin P Recombinant Antibody), specifically binds to P-selectin with a dissociation constant (Kd) of 9.9 nM. It effectively prevents the interaction between P-selectin and P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide, with a half-maximal inhibitory concentration (IC50) of 1.9 µg/mL, and robustly impedes cell adhesion [1] [2] [3].

Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targeting Fibroblast Activating Protein (FAP).Sibrotuzumab is used in the study of colorectal cancer and non-small cell lung cancer.

Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor

Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.

Atezolizumab (anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD-L2 with PD-1.

Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9).

Pembrolizumab is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that impairs the ability of HER2 to bind to other members of the HER family.

Nivolumab (anti-PD-1) is a genetically engineered fully human immunoglobulin Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1PD-1PCD-1) with immune checkpoint inhibitory and antineoplastic activities.

Infliximab is a humanized antibody against tumor necrosis factor α TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis.

Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis.

Bevacizumab, a humanized monoclonal antibody, specifically and with high affinity binds to all isoforms of VEGF-A.

Ensituximab (NEO-102) is a quasi-selective IgG1 monoclonal antibody against the MUC5AC variant with anti-tumour activity that inhibits colorectal and pancreatic cancer.

Zilovertamab (UC-961) is a humanized anti-ROR1 monoclonal antibody that cuts off the WNT5A-induced ROR1 signaling pathway and shows anti-proliferative activity in ovarian and endometrial cancer cells. It can be used to study lymphatic cancer.

Gemtuzumab(CMA-676) is a monoclonal antibody directed against the CD33 antigen and consists of a recombinant humanized IgG4 antibody.Gemtuzumab can be used to synthesize Gemtuzumab ozogamicin, an antibody coupled compound (ADC) Gemtuzumab is used in the study of acute myeloid leukemia.

Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.